Safety and tolerability of AZD8055 in Japanese patients with advanced solid tumors; a dose-finding phase I study-Reference-Cited by-同舟云学术

Safety and tolerability of AZD8055 in Japanese patients with advanced solid tumors; a dose-finding phase I study

Published:2012-07-28 Issue:3 Volume:31 Page:677-684
ISSN:0167-6997
Container-title:Investigational New Drugs
language:en
Short-container-title:Invest New Drugs

Author:

Asahina Hajime,Nokihara Hiroshi,Yamamoto Noboru,Yamada Yasuhide,Tamura Yosuke,Honda Kazunori,Seki Yoshitaka,Tanabe Yuko,Shimada Hitoshi,Shi Xiaojin,Tamura Tomohide

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Pharmacology,Oncology

Link

http://link.springer.com/content/pdf/10.1007/s10637-012-9860-4.pdf

Reference17 articles.

1. Guertin DA, Sabatini DM (2007) Defining the role of mTOR in cancer. Cancer Cell 12:9–22

2. Jefferies HB, Fumagalli S, Dennis PB, Reinhard C, Pearson RB, Thomas G (1997) Rapamycin suppresses 5′TOP mRNA translation through inhibition of p70s6k. EMBO J 16:3693–3704

3. Manning BD, Cantley LC (2007) AKT/PKB signaling: navigating downstream. Cell 129:1261–1274

4. Vivanco I, Sawyers CL (2002) The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer 2:489–501

5. Vilar E, Perez-Garcia J, Tabernero J (2011) Pushing the envelope in the mTOR pathway: the second generation of inhibitors. Mol Cancer Ther 10:395–403

Cited by 33 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Phase I dose escalation study and pilot efficacy analysis of LXI-15029, a novel mTOR dual inhibitor, in Chinese subjects with advanced malignant solid tumors;BMC Cancer;2023-12-06

2. The molecular genetics of PI3K/PTEN/AKT/mTOR pathway in the malformations of cortical development;Genes & Diseases;2023-07

3. Potential Therapeutic Strategies to Combat HCC;Current Molecular Pharmacology;2022-12

4. Metabolic Reprogramming in Cancer Cells: Emerging Molecular Mechanisms and Novel Therapeutic Approaches;Pharmaceutics;2022-06-19

5. mTOR as an eligible molecular target for possible pharmacological treatment of nonalcoholic steatohepatitis;European Journal of Pharmacology;2022-04